President Trump wants to change the regulations on cannabis. Will this change Canopy into a profitable stock?Canopy Growth (CGC +49.56%) stock soared 17% through 12:50 p.m. ET Friday on some positive marijuana news out of the White House.As The Washington Post reports, President Trump aims to reschedule pot in the near future. This is not quite "legalization", but it's apparently enough to get marijuana investors excited today. President Trump's Christmas gift to marijuana investorsThe Post cites six perso ...

Core Insights - U.S. stocks experienced a decline, with the Nasdaq Composite dropping over 400 points on Friday [1] - RH reported third-quarter earnings of $1.71 per share, missing analyst estimates by 20.87%, while quarterly revenue of $883.81 million exceeded expectations [1] Company Performance - RH shares increased by 5.8% to $162.14 following the earnings report [2] - Lululemon Athletica Inc. saw a 10.1% gain to $205.80 after beating third-quarter estimates and raising full-year guidance [3] - Frequency Electronics Inc. reported better-than-expected second-quarter sales, leading to a 27.2% increase in share price to $45.84 [3] - CCC Intelligent Solutions Holdings Inc. announced a $500 million share repurchase authorization, resulting in a 6.3% increase in share price to $7.68 [3] Market Reactions - Canopy Growth Corp. shares rose 35.4% to $1.53 due to potential federal marijuana regulation changes [3] - Rivian Automotive Inc. gained 14.9% to $18.88 after announcing entry into the autonomous driving sector with a new AI chip [3] - Clear Secure Inc. experienced an 11.3% increase to $40.36 after an upgrade from JP Morgan [3]

Core Viewpoint - Cannabis stocks experienced a significant surge, with Tilray Brands (TLRY.US) rising over 32%, Canopy Growth (CGC.US) increasing over 23%, SNDL (SNDL.US) up over 19%, Aurora Cannabis (ACB.US) gaining over 11%, and Cronos Group (CRON.US) climbing over 5% due to reports that President Donald Trump is considering reclassifying cannabis to a lower harm category [1] Group 1 - Tilray Brands (TLRY.US) saw an increase of over 32% [1] - Canopy Growth (CGC.US) rose by more than 23% [1] - SNDL (SNDL.US) experienced a gain of over 19% [1] Group 2 - Aurora Cannabis (ACB.US) increased by more than 11% [1] - Cronos Group (CRON.US) rose by over 5% [1] - Reports indicate that Trump is considering moving cannabis from Schedule I to Schedule III, indicating a potential shift in regulatory stance [1]

Core Insights - The reclassification of the drug is expected to alleviate tax burdens on cannabis companies [1] Industry Impact - Cannabis companies will benefit from reduced tax liabilities due to the reclassification of the drug [1]

Core Viewpoint - The stock prices of major cannabis companies surged significantly following reports of President Trump's plans to relax federal regulations on marijuana, with notable increases in premarket trading [1][2]. Group 1: Stock Price Movements - Tilray Brands (NASDAQ:TLRY) saw a price increase of 34.88%, while Canopy Growth (NASDAQ:CGC) rose by 27.46% in premarket trading [1]. - Other companies also experienced substantial gains: Aurora Cannabis Inc. (NASDAQ:ACB) surged 20%, Cronos Group Inc. (NASDAQ:CRON) gained 19%, Organigram Global Inc. (NASDAQ:OGI) rose 12%, and SNDL Inc. (NASDAQ:SNDL) increased by 34.7% [1]. Group 2: Regulatory Changes - The surge in stock prices was attributed to news that Trump plans to instruct federal agencies to reclassify marijuana as a Schedule III drug, which would change its regulatory status [2][3]. - This reclassification would subject cannabis companies to different tax regulations, potentially attracting more investments and placing marijuana in the same category as substances like steroids and Tylenol with codeine [3]. Group 3: Historical Context - Trump had previously hinted at this reclassification in August, indicating a consistent approach towards cannabis regulation [3]. - The anticipated change is expected to occur early next year, moving marijuana from a category that includes heroin to a lower tier for less dangerous substances [4].

Core Viewpoint - The potential reclassification of cannabis by President Trump from Schedule I to Schedule III is expected to significantly benefit the cannabis industry, leading to a surge in stock prices for major cannabis producers in the U.S. [1][2] Group 1: Market Reaction - Major cannabis producers saw substantial stock price increases in pre-market trading, with Tilray Brands (TLRY.US) rising over 30%, Canopy Growth (CGC.US) up 23%, Aurora Cannabis (ACB.US) increasing by 20%, SNDL (SNDL.US) gaining 14%, and Cronos Group (CRON.US) up 12% [1] - The market response indicates strong investor optimism regarding the potential regulatory changes surrounding cannabis [1] Group 2: Regulatory Context - President Trump is considering moving cannabis from Schedule I, which indicates no medical use and high abuse potential, to Schedule III, which includes substances with accepted medical uses but some potential for abuse [1][2] - Schedule III drugs include substances like ketamine and anabolic steroids, while Schedule I includes LSD and heroin [2] - The Biden administration previously proposed a similar reclassification in March 2024, but the DEA canceled related hearings [2] Group 3: Political and Industry Implications - Trump's discussions with key officials and cannabis industry executives suggest a serious consideration of the reclassification, which could alleviate criminal penalties for personal use and remove certain federal tax and business barriers [2] - The reclassification could improve the operating environment for legal cannabis businesses and their employees [2] - Robert F. Kennedy Jr., nominated by Trump for the Department of Health and Human Services, has advocated for ending cannabis criminalization and implementing a regulated sales system [3]

Group 1 - Cannabis stocks experienced significant gains, with Tilray Brands surging over 28% and Canopy Growth jumping 23% in premarket trading [1] - Innovative Industrial Properties, a cannabis facility operator, also saw an increase of more than 6% [1] - The surge in cannabis stocks was attributed to reports of President Donald Trump planning to ease federal restrictions on marijuana [1] Group 2 - Trump is expected to instruct agencies to reclassify marijuana as a Schedule III drug, which would alter tax regulations for cannabis companies and promote investment [2] - The reclassification would move marijuana from a category that includes heroin to a lower tier with less dangerous drugs, such as steroids and Tylenol with codeine, and is anticipated to occur early next year [2] - This change in classification was previously suggested by Trump in August, highlighting ongoing discussions about marijuana's legal status [3] Group 3 - Despite broader acceptance of cannabis, pot stocks have faced challenges since many went public approximately seven years ago, with Tilray shares down 36% prior to the recent surge [3]

Core Viewpoint - Canopy Growth's stock price experienced a significant increase in pre-market trading due to positive investor sentiment regarding cannabis rescheduling, with shares rising over 35% to $1.530, resulting in a higher market capitalization [1] Group 1 - Canopy Growth's stock price surged by over 35% in pre-market trading [1] - The stock price increase brought Canopy Growth's market capitalization to a notable level [1]

Core Insights - The Canadian cannabis sector is experiencing renewed interest from traders and long-term investors despite unpredictable market conditions, with leading companies showing resilience and strategic progress [1][2] - The industry faces challenges such as slower domestic growth, tighter financing conditions, and heavy price competition, but operators are expanding internationally and preparing for potential U.S. policy changes [1][2] - Financial discipline is becoming a key theme, with companies reducing costs and improving margins, indicating signs of maturity in the sector [3] Industry Overview - The global cannabis landscape is evolving, with European countries expanding medical programs and Germany advancing legalization, creating export opportunities for Canadian producers [2] - U.S. federal reform remains uncertain, but companies with indirect exposure to the U.S. market could benefit from any policy changes [2] Company Highlights - **Tilray Brands, Inc.**: Continues to expand internationally while improving financial performance, reporting Q1 fiscal 2026 revenue of approximately $210 million, with positive net income and over $250 million in cash [5][8] - **Canopy Growth Corporation**: Gaining traction after restructuring, with Q2 fiscal 2026 revenue growth driven by Canadian adult-use sales and improved medical demand, alongside a significant reduction in net loss [9][10][11] - **Village Farms International, Inc.**: Transitioned to cannabis cultivation with strong financial performance, reporting double-digit revenue growth and positive net income for multiple quarters, supported by efficient operations and rising international demand [12][14] Financial Performance - Tilray's revenue growth is attributed to stronger Canadian sales and rising international demand, with improved margins and better cost control [8] - Canopy's revenue growth is driven by better brand strength and retail penetration in Canada, with improved gross margins and liquidity [10][11] - Village Farms has shown strong financial performance with high gross margins and positive net income, benefiting from disciplined cost controls and scalable growing capacity [14] Strategic Positioning - Companies are building stronger platforms and expanding their international footprints, positioning themselves for potential U.S. policy shifts [1][2] - Tilray's diverse product portfolio and strong distribution network in Canada and Europe position it well for future growth [5] - Canopy's integrated platform in the U.S. through partnerships provides a strong multi-state reach despite not holding direct cannabis licenses [9][11] - Village Farms' international presence and potential for THC production in the U.S. could enhance its growth prospects [12][14]

Core Viewpoint - Canadian Gold Corp. is advancing its Phase 4 drill program at the Tartan Mine, with promising results indicating potential for a mine restart, particularly in the Main Zone's Western Flank [1][3] Drilling Results - The drilling program has focused on three main areas: the Main Zone's Western Flank, the South Zone, and prospecting near the Tartan Mine [2] - Significant assay results from the Main Zone's Western Flank include 12.3 gpt gold over 14.0 metres, 8.2 gpt gold over 9.9 metres, and 10.7 gpt gold over 4.5 metres [3] - A total of 31 out of 35 holes (89%) have intersected potentially economic mineralization within the Main Zone since the start of the drilling program [4] South Zone Exploration - Drilling in the South Zone aims to expand resource size for higher production potential, with notable results including 5.2 gpt gold over 5.0 metres and 4.4 gpt gold over 4.0 metres [5] - TLSZ25-41 reported a significant intercept of 82.0 metres at 1.3 gpt Au, indicating the presence of higher-grade sections within broader mineralized envelopes [5] Near Mine Target Generation - Drill target generation on the Tartan West property has confirmed multiple areas of high-grade gold mineralization, with grab samples assaying up to 28.9 gpt gold [6] - The Tartan Shear presents significant exploration potential for hosting similar gold mineralization, aligning with future infrastructure investments [7] Company Overview - Canadian Gold Corp. is focused on expanding the high-grade gold resource at the Tartan Mine, which has a 2017 indicated mineral resource estimate of 240,000 oz gold at 6.32 g/t [14] - The company also holds exploration properties in Ontario and Quebec, adjacent to major gold mines and projects [14]